Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

http://www.wikidata.org/entity/Q35031403

about

Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51 Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop Mechanism Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.Evaluation of artemisinins for the treatment of acute myeloid leukemia.Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model Molecular therapeutic approaches for pediatric acute myeloid leukemia.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.NFATc1 as a therapeutic target in FLT3-ITD-positive AML.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

P2860

Q28239708-B0F4A82D-4A51-4E19-8EA8-01F1FC10FC26 Q28535006-A530B9A9-4D73-4166-AB08-8598B6105CA7 Q33618658-4CF8E775-DD87-4C81-9E81-A6298E9691D0 Q33633267-A685581F-ECFB-43A2-97BB-1B8704B492DA Q34656484-00E3DB30-C35F-4596-B5E4-F20E804BE82B Q34689078-85719614-9903-404C-98D5-0148A4649E06 Q34774854-833030E6-2476-423F-BA93-AEAD4D0E052F Q34975439-1468D875-9FD1-44D1-93D8-FB9CB7E0378C Q35172210-5D3B17C0-146A-4DA5-9634-180A9BEB1897 Q36237312-8DB1452B-D478-4189-BF44-A16D07DB0B5D Q36463168-E47C90C0-1092-4EC5-AFBD-AA939566B4E4 Q36544596-C559BD62-2DDC-4AF1-8953-3641102414F2 Q36998913-228578CA-5D24-402C-8D2E-396A6FFF21DA Q37033027-74D98F09-2633-4369-8014-DC33016BE854 Q37334711-263B0594-3450-4A8D-B425-2EAE0DE020AE Q37379676-B46A4DA9-437D-4E5A-870F-16E1578222F4 Q37594395-A686FADC-5FF9-49BB-AA51-F6DCA7C184C6 Q37598626-BCA3BCB8-B841-4370-BC2F-4AE25CF7A64D Q37640370-E0A4FFE6-4018-4EF9-8AD7-C94AAFABC3CC Q37643136-A635EB49-478F-4DA7-8262-E526679EC3B0 Q38061500-509910D9-38C8-4CF7-8CBC-001EAD7D8611 Q38201503-247F2545-6222-4B28-8134-A141839A5BC0 Q38336723-FFF65C30-96B0-4640-BE8B-577B8E5F4FE2 Q40937224-70481DFE-9C82-4738-B0C0-FC3F46AD4718 Q41763725-B212BFD1-117E-43B8-85EC-1CAE4614EC51 Q46931556-62131D7A-3290-42FA-938E-11951792647F Q51134492-8CF169F0-6CEF-474F-9066-7F15D790DB3E Q54252958-EE306C9B-8868-4697-BAF4-CB9265119ACC

P2860

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

http://www.wikidata.org/entity/Q35031403

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@ast

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@en

type

label

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@ast

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@en

prefLabel

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@ast

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@en

P1433

Q35031403-2A80E072-D419-4750-B246-F30AB1165EF4

P1476

Q35031403-AFF8F475-5BD8-4861-BB9A-36FBEBA6A054

P2093

Q35031403-12238C34-19DA-4414-9F16-70371D33B9DA

Q35031403-14CE81E7-8ED2-4B05-AF15-9C9DD9E6E42A

Q35031403-217E5FE8-B3DE-4D1E-AD26-B12D5673C8F8

Q35031403-2EBB7B62-BB9E-4CFA-A3E2-85CACC46843D

Q35031403-3106900B-5AD5-4EC4-9D20-3382E089D686

Q35031403-3955791C-BCB0-4552-8088-01A55D3A55BF

Q35031403-90C28C2F-B9B1-4D96-8682-00A6A2A85C29

Q35031403-99C11A41-A16A-4C8B-90FA-AACDB60E106F

Q35031403-9EDF24C0-0960-4FFE-A567-64F1E6ECDA5D

Q35031403-C3973999-B1C1-410E-AD8C-BD2FF428BC8A

P2860

Q35031403-090E7736-80DB-4E25-BA49-DCF381BB9A0A

Q35031403-0B1277C9-C14C-4190-9DDA-7A07C3CE48DC

Q35031403-0C08DAEF-BCAA-47ED-BDD4-2E62AA1BB4F2

Q35031403-0F7B5A71-CF91-4F39-924A-BA514CB95346

Q35031403-33FDD90F-BDC1-4E65-9CBF-C6BB83DDCAA8

Q35031403-34CD59CD-AB48-4135-A706-E4F78E608988

Q35031403-362D25BB-6EEF-4073-915B-F70787621706

Q35031403-36DF2033-19F7-42E5-90E3-F5B27B54F37C

Q35031403-38C478DE-FD3F-4C63-BCD7-B7773C7D9B36

Q35031403-45AA69C4-07DB-488B-BAAB-02657D3A9350

P304

Q35031403-C999021B-01DF-4E90-AF7C-7A21EDB904F6

P31

Q35031403-643CA6EF-5F73-4B00-9456-C764FB636EEA

P356

Q35031403-0CEB2737-C7A4-450E-A38C-555092031472

P407

Q35031403-678B4DB9-EF33-4D13-946A-5549689E710A

P433

Q35031403-4383E200-3FE4-4CEC-BEA5-0067DCEC8055

P478

Q35031403-2ED061F3-72A7-4F3D-A1BC-9B3055779AF9

P577

Q35031403-4F43AECD-BFF3-4BD1-9DE2-74FB60EE151F

P5875

Q35031403-332FD160-6B6B-43DC-B8EA-5C30D46AF8F1

P698

Q35031403-AFC23621-2779-4E9F-ACDB-FCE762032A46

P921

Q35031403-B184A392-F6E5-4867-95AE-6E26E7ACED2E

P932

Q35031403-5C5C91AB-AE6C-4E0B-A300-A9DACA1E1FFF

P356

P1433

Journal of the National Cancer Institute

P1476

Activity of the multikinase in ...... ine in acute myeloid leukemia.

@en

P2093

Charles Rose

http://www.w3.org/2001/XMLSchema#string

Christopher Calabrese

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Hiroto Inaba

http://www.w3.org/2001/XMLSchema#string

Hongmei Niu

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Rubnitz

http://www.w3.org/2001/XMLSchema#string

Jerold E Rehg

http://www.w3.org/2001/XMLSchema#string

John C Panetta

http://www.w3.org/2001/XMLSchema#string

Sharyn D Baker

http://www.w3.org/2001/XMLSchema#string

Shelley Orwick

http://www.w3.org/2001/XMLSchema#string

P2860

MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

A small molecule-kinase interaction map for clinical kinase inhibitors

''R"--project for statistical computing

Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

P304

893-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR107

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51045755

http://www.w3.org/2001/XMLSchema#string

P698

21487100

http://www.w3.org/2001/XMLSchema#string

P921

P932

3110171

http://www.w3.org/2001/XMLSchema#string